CD4 and neoplasm: This promising divalent therapy Nanovaccine_siTGF‐β1 + Pexidartinib boosted T‐cell infiltration into tumors (Figure 4A), resulting in the highest levels of tumor‐infiltrating CD4+ T cells (Figure 4B), and CD8+ T cells (Figure 4C) (p < 0.0001) (Figure S10, Supporting Information).